Perspectives on Ensifentrine and Its Therapeutic Potential in the Treatment of COPD: Evidence to Date

Abstract

Ensifentrine is a novel inhalational phosphodiesterase (PDE)3 and PDE4 inhibitor which improves bronchodilation and decreases inflammatory markers by acting locally on the bronchial tissue, with minimal systemic effects. Both preclinical and clinical trials have demonstrated benefits of this therapy, including improvement in lung function and reduction in exacerbations. This therapy is currently under review by the US Food and Drug Administration with a decision expected in 2024.

Keywords:

• chronic obstructive pulmonary disease
• therapy
• phosphodiesterase inhibitor

Disclosure

Drs. Faruqi and Khan report no conflicts of interest. Dr. Mannino is a consultant to GlaxoSmithKline, AstraZeneca, Regeneron, Genentech and The COPD Foundation, receives royalties from Up to Date, and is an expert witness on behalf of people suing the tobacco and vaping industries.